16 results found.

Confirmed Diagnosis of ß-thalassemia Major Clinical Trial using Autologous CD34+ cells transduced with TNS9.3.55

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- A Phase I Clinical Trial for the Treatment of ß-Thalassemia Major With Autologous CD34+ Hematopoietic Progenitor Cells Transduced With TNS9.3.55 a Lentiviral Vector Encoding the Normal Human ß-Globin Gene.
Autologous CD34+ cells transduced with TNS9.3.55

Transfusional Iron Overload, Thalassemia Major, Sickle Cell Disea Clinical Trial using Hepatic biomagnetic susceptibility measurement

Columbia University - Recruiting 5 years to 80 years.
- High-Tc Susceptometer to Monitor Transfusional Iron Overload (NSR Device).
Hepatic biomagnetic susceptibility measurement

Non-transfusion Dependent Thalassemia Clinical Trial using ICL670 deferasirox

Novartis - Recruiting 10 years or older.
- An Open Label, Multi-center, Efficacy and Safety Study of Deferasirox in Iron Overloaded Patients With Non-transfusion Dependent Thalassemia.
ICL670 deferasirox

Congenital Hemolytic Anemia, or Diamond-Blackfan Anemia Clinical Trial using Radiotherapy; Alemtuzumab (Campath ); Sirolimus (Rapamune )

National Institutes of Health Clinical Center (CC) - Recruiting 2 years to 65 years.
- Non-Myeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation For Severe Congenital Anemias Including Sickle Cell Disease, Thalassemia, and Diamond Blackfan Anemia.
Radiotherapy; Alemtuzumab (Campath ); Sirolimus (Rapamune )

Peripheral Blood Stem Cell Transplantation, Anemia, Sickle Cell, Clinical Trial using PBMC Transplant; Alemtuzumab (Campath ); Sirolimus (Rapamune ); Cyclophosphamide (Cytoxan ); Low Dose Irradiation

National Institutes of Health Clinical Center (CC) - Recruiting 2 years or older.
- Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease and Beta-Thalassemia.
PBMC Transplant; Alemtuzumab (Campath ); Sirolimus (Rapamune ); Cyclophosphamide (Cytoxan ); Low Dose Irradiation

Thalassemia Clinical Trial using Deferasirox or Deferoxamine or Combination (Deferoxamine and Deferiprone); Amlodipine

Aga Khan University - Recruiting 6 years to 20 years.
- Effect of L-type Calcium Channel Blocker (Amlodipine) on Myocardial Iron Deposition in Thalassemic Patients With Moderate to Severe Myocardial Iron Deposition: A Randomized Pilot Study.
Deferasirox or Deferoxamine or Combination (Deferoxamine and Deferiprone); Amlodipine

Transfusional Iron Overload, or Beta-Thalassemia Clinical Trial using SPD602 (SSP-004184)

Shire Development LLC - Recruiting 6 years to 17 years.
- A Phase 2, Open Label, Multi-Center, Single-Dose Pharmacokinetics, and Multiple Dose Study of the Safety, Efficacy and Tolerability of SSP-004184 (SPD602) in a Pediatric Population With Transfusional Iron Overload.
SPD602 (SSP-004184)

Sickle Cell Anemia, Sickle Cell-hemoglobin C Disease, or Sickle C Clinical Trial using Fludarabine; Cytarabine; Cellular Infusions; Total Body Irradiation; Cyclophosphamide; Bortezomib; Rituximab; Plasmapheresis

Thomas Jefferson University - Recruiting 18 years to 45 years.
- Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Sickle Cell Anemia From HLA Matched or Partially-Matched Related Donors.
Fludarabine; Cytarabine; Cellular Infusions; Total Body Irradiation; Cyclophosphamide; Bortezomib; Rituximab; Plasmapheresis

Sickle Cell Disease and Thalassemia Clinical Trial using Donor Stem Cell Transplantation

University of Texas Southwestern Medical Center - Recruiting 18 years to 45 years.
- Nonmyeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease and Thalassemia.
Donor Stem Cell Transplantation

Thalassemia, Non-transfusion Dependent Thalassemia, Myelodysplast Clinical Trial using Single arm MRI test

Novartis - Recruiting 12 years or older.
- An Epidemiological Study to Assess the Prevalence of Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study).
Single arm MRI test

Beta-thalassemia Major Clinical Trial using LentiGlobinr BB305 Drug Product

bluebird bio - Recruiting 18 years to 35 years.
- A Phase 1/2 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy in Subjects With á-Thalassemia Major by Transplantation of Autologous CD34+ Cells Transduced Ex Vivo With a Lentiviral á-A(T87Q)-Globin Vector (LentiGlobinr BB305 Drug Product).
LentiGlobinr BB305 Drug Product

Thalassemia, Sickle Cell Disease, or Myelodysplasia Clinical Trial using Blood sample

Assistance Publique - H“pitaux de Paris - Recruiting 6 years or older.
- Multicenter Observational Study on Myocardial Iron Overload in 3 Multitransfused Populations.
Blood sample

Thalassemia Clinical Trial using Nutritional recommendations

HaEmek Medical Center, Israel - Recruiting 5 years to 40 years.
- Endocrine and Nutritional Assessment in B Thalassemia Major - A Clinical Trial.
Nutritional recommendations

Thalassemia, or Iron Deficiency Clinical Trial using Observation of results from laboratory tests

HaEmek Medical Center, Israel - Recruiting 17 years to 50 years.
- Detection of á Thalassemia Carriers by Red Cell Parameters Obtained From the H2 Automatic Counter. A Clinical Retrospective Study..
Observation of results from laboratory tests

Thalassemia, or Sickle Cell Disease Clinical Trial using Medical Chart Summary

HaEmek Medical Center, Israel - Recruiting 5 years to 45 years.
- Iron Overload and Growth Velocity in Thalassemia and Sickle Cell Anemia.
Medical Chart Summary